Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of adebrelimab + carboplatin + etoposide + thoracic palliative radiotherapy in first-line extensive-stage small cell lung cancer
ChiCTR2300079125Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
adebrelimabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300079125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079125.